Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 1/2 1

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Genitourinary 1

Conditions

Neoplasms 2Breast Neoplasms 2Triple Negative Breast Neoplasms 1Recurrence 1Prostatic Neoplasms 1Ovarian Neoplasms 1Muscle Invasive Bladder Cancer 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Glioblastoma 1Fallopian Tube Neoplasms 1Disease 1Advanced Solid Malignancies 1Advanced Metastatic Breast Cancer 1Advanced Cancer 1

Interventions

pembrolizumab 82Paclitaxel 71Gemcitabine 66Carboplatin 61Cisplatin 46Docetaxel 44Bevacizumab 41Nivolumab 33Irinotecan 31Fluorouracil 29Pemetrexed 28Cyclophosphamide 26Cetuximab 26Capecitabine 26Erlotinib Hydrochloride 22venetoclax 21trametinib 21Leucovorin 20Sorafenib 17Albumin-Bound Paclitaxel 17Afatinib 17130-nm albumin-bound paclitaxel 17Topotecan 16Radiotherapy 16Oxaliplatin 16fludarabine 15regorafenib 14budigalimab 14atezolizumab 14Ipilimumab 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Neoplasms × vistusertib × Clear all
NCT02064608 2019-07-17

CaNCaP02

Cambridge University Hospitals NHS Foundation Trust

Phase 1 Completed
23 enrolled
Genitourinary

Disease, Neoplasms, Prostatic Neoplasms

NCT01026402 2016-02-11

Study to Assess the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Efficacy of AZD2014

AstraZeneca

Phase 1 Completed
172 enrolled 35 charts
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡